First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced the publication of two patent applications for its enhanced enteric microgranule delivery formulation of adrulipase. The patents cover composition of matter and methods of use claims and were published by both the United States Patent and Trademark Office (USPTO) and the International Bureau of the World International Patent Organization (WIPO) under the Patent Cooperation Treaty (PCT). These patents strengthen First Wave's intellectual property estate and highlight their ability to introduce important drug innovations for underserved disease indications.
The enhanced enteric microgranule delivery formulation of adrulipase is being developed for the treatment of malabsorption. James Sapirstein, President and CEO of First Wave BioPharma, emphasized that possessing multilayered intellectual property is an important value driver for the company as they await topline data from their Phase 2 SPAN clinical trial investigating this formulation.
First Wave BioPharma has filed several patent applications protecting its enteric microgranule delivery formulation of adrulipase. They are